Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
All content for Pharma Unlimited is the property of Wolters Kluwer and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
In this episode, Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer at Novartis speaks with Pharma Unlimited podcast host, Bertrand Bodson, about ethics and the ability for them to keep up with innovation in the pharma industry.
Pharma Unlimited
Welcome to Pharma Unlimited, by Wolters Kluwer. Join host Bertrand Bodson as we go under the microscope to examine some of the biggest issues facing the pharma sector. What will the arrival of Big Tech mean for innovation, risk, and regulation? How will the industry develop new treatments in a post-pandemic world? This five-part series will feature some of the leading lights in life sciences and technology and explore some of the biggest questions facing the pharma industry.
